| Fortive Corporation | ||||||||
| (Exact Name of Registrant as Specified in Its Charter) | ||||||||
| 001-37654 | 47-5654583 | |||||||
| (Commission File Number) | (IRS Employer Identification No.) | |||||||
| 6920 Seaway Blvd | |||||||||||
| Everett, | WA | 98203 | |||||||||
| (Address of principal executive offices) | (Zip code) | ||||||||||
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||
| Title of each class | Trading symbol | Name of each exchange on which registered | ||||||
| Common stock, par value $0.01 per share | FTV | New York Stock Exchange | ||||||
3.700% Notes due 2026  | FTV26A  | New York Stock Exchange  | ||||||
3.700% Notes due 2029  | FTV29  | New York Stock Exchange  | ||||||
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS | |||||||
| (d) | Exhibits: | |||||||
| Exhibit No. | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
| FORTIVE CORPORATION | |||||||||||
| Date: | October 29, 2025 | By: | /s/ Daniel B. Kim | ||||||||
| Daniel B. Kim | |||||||||||
| Vice President - Associate General Counsel and Secretary | |||||||||||

Fortive Continuing Operations  | Q3-25  | Q3-24  | Variance  | ||||||||
Revenue  | $1,027M | $1,004M | 2.3% / 1.9% (reported / core)  | ||||||||
GAAP Net Income  | $117M | $111M | 4.9% | ||||||||
GAAP Net Income margin  | 11.4% | 11.1% | 30 bps | ||||||||
Adj. EBITDA  | $309M | $280M | 10.4% | ||||||||
Adj. EBITDA margin  | 30.1% | 27.9% | 220 bps | ||||||||
GAAP diluted net earnings per share  | $0.35 | $0.32 | 9.4% | ||||||||
Adj. diluted net earnings per share  | $0.68 | $0.59 | 15.3% | ||||||||
GAAP Operating cash flow  | $295M | $305M | (3.3)% | ||||||||
Free cash flow  | $266M | $283M | (6.0)% | ||||||||
| TTM GAAP Operating cash flow | $1,019M | $961M | 6.1% | ||||||||
| TTM Free cash flow | $922M | $874M | 5.5% | ||||||||
Intelligent Operating Solutions  | Q3-25  | Q3-24  | Variance  | ||||||||
Revenue  | $699M | $681M | 2.6% / 2.2% (reported / core)  | ||||||||
GAAP Operating profit  | $181M | $169M | 6.9% | ||||||||
GAAP Operating margin  | 25.9% | 24.8% | 110 bps | ||||||||
Adj. EBITDA  | $242M | $227M | 6.7% | ||||||||
Adj. EBITDA margin  | 34.6% | 33.3% | 130 bps | ||||||||
Advanced Healthcare Solutions  | Q3-25  | Q3-24  | Variance  | ||||||||
Revenue  | $328M | $322M | 1.9% / 1.1% (reported / core)  | ||||||||
GAAP Operating profit  | $43M | $37M | 15.8% | ||||||||
GAAP Operating margin  | 12.9% | 11.4% | 150 bps | ||||||||
Adj. EBITDA  | $92M | $87M | 6.6% | ||||||||
Adj. EBITDA margin  | 28.1% | 26.9% | 120 bps | ||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| September 26, 2025 | September 27, 2024 | September 26, 2025 | September 27, 2024 | ||||||||||||||||||||
Sales  | 1,027.1 | 1,003.7 | 3,036.6 | 3,008.1 | |||||||||||||||||||
Cost of sales  | (377.9) | (362.2) | (1,104.4) | (1,084.5) | |||||||||||||||||||
| Gross profit | 649.2 | 641.5 | 1,932.2 | 1,923.6 | |||||||||||||||||||
| Operating costs: | |||||||||||||||||||||||
| Selling, general and administrative | (427.6) | (407.5) | (1,244.3) | (1,233.4) | |||||||||||||||||||
| Research and development | (62.0) | (62.0) | (193.2) | (186.1) | |||||||||||||||||||
| Operating profit | 159.6 | 172.0 | 494.7 | 504.1 | |||||||||||||||||||
| Non-operating income (expense), net: | |||||||||||||||||||||||
| Interest expense, net | (25.4) | (37.1) | (89.5) | (119.8) | |||||||||||||||||||
| Other non-operating income (expense), net | 0.8 | (25.8) | 3.1 | (58.2) | |||||||||||||||||||
| Earnings from continuing operations before income taxes | 135.0 | 109.1 | 408.3 | 326.1 | |||||||||||||||||||
| Income taxes | (18.0) | 2.4 | (67.1) | (36.8) | |||||||||||||||||||
| Net earnings from continuing operations | 117.0 | 111.5 | 341.2 | 289.3 | |||||||||||||||||||
| Net earnings (loss) from discontinued operations | (62.0) | 110.1 | 52.3 | 334.8 | |||||||||||||||||||
| Net earnings | $ | 55.0 | $ | 221.6 | $ | 393.5 | $ | 624.1 | |||||||||||||||
| Net earnings per common share from continuing operations: | |||||||||||||||||||||||
| Basic | $ | 0.35 | $ | 0.32 | $ | 1.01 | $ | 0.82 | |||||||||||||||
| Diluted | $ | 0.35 | $ | 0.32 | $ | 1.00 | $ | 0.82 | |||||||||||||||
| Net earnings per common share from discontinued operations: | |||||||||||||||||||||||
| Basic | $ | (0.19) | $ | 0.31 | $ | 0.16 | $ | 0.96 | |||||||||||||||
| Diluted | $ | (0.19) | $ | 0.31 | $ | 0.15 | $ | 0.94 | |||||||||||||||
| Net earnings per share: | |||||||||||||||||||||||
| Basic | $ | 0.17 | $ | 0.63 | $ | 1.17 | $ | 1.78 | |||||||||||||||
| Diluted | $ | 0.16 | $ | 0.63 | $ | 1.16 | $ | 1.76 | |||||||||||||||
| Average common stock and common equivalent shares outstanding: | |||||||||||||||||||||||
| Basic | 330.8 | 349.2 | 337.2 | 350.7 | |||||||||||||||||||
| Diluted | 333.4 | 352.3 | 339.9 | 354.4 | |||||||||||||||||||
| Certain amounts may not sum due to rounding. | |||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| September 26, 2025 | September 27, 2024 | September 26, 2025 | September 27, 2024 | ||||||||||||||||||||
| Sales: | |||||||||||||||||||||||
| Intelligent Operating Solutions | $ | 698.8 | $ | 681.3 | $ | 2,086.6 | $ | 2,062.3 | |||||||||||||||
| Advanced Healthcare Solutions | 328.3 | 322.4 | 950.0 | 945.8 | |||||||||||||||||||
| Total | $ | 1,027.1 | $ | 1,003.7 | $ | 3,036.6 | $ | 3,008.1 | |||||||||||||||
| Operating Profit: | |||||||||||||||||||||||
| Intelligent Operating Solutions | $ | 180.7 | $ | 169.0 | $ | 526.1 | $ | 507.2 | |||||||||||||||
| Advanced Healthcare Solutions | 42.5 | 36.7 | 100.0 | 95.8 | |||||||||||||||||||
Other (a)  | (63.6) | (33.7) | (131.4) | (98.9) | |||||||||||||||||||
| Total | $ | 159.6 | $ | 172.0 | $ | 494.7 | $ | 504.1 | |||||||||||||||
| Operating Margins: | |||||||||||||||||||||||
| Intelligent Operating Solutions | 25.9 | % | 24.8 | % | 25.2 | % | 24.6 | % | |||||||||||||||
| Advanced Healthcare Solutions | 12.9 | % | 11.4 | % | 10.5 | % | 10.1 | % | |||||||||||||||
| Total | 15.5 | % | 17.1 | % | 16.3 | % | 16.8 | % | |||||||||||||||
| (a) Operating profit amounts in the Other category consist of unallocated corporate costs and other costs not considered part of our evaluation of reportable segment operating performance. | |||||||||||||||||||||||
| As of | |||||||||||
| September 26, 2025 | December 31, 2024 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and equivalents | $ | 430.8 | $ | 813.3 | |||||||
Accounts receivable less allowance for doubtful accounts of $18.7 and $19.4, respectively  | 633.6 | 661.3 | |||||||||
| Inventories: | |||||||||||
| Finished goods | 190.8 | 151.9 | |||||||||
| Work in process | 12.2 | 15.3 | |||||||||
| Raw materials | 107.6 | 102.6 | |||||||||
| Inventories | 310.6 | 269.8 | |||||||||
| Prepaid expenses and other current assets | 303.4 | 233.6 | |||||||||
| Current assets, discontinued operations | 53.2 | 614.3 | |||||||||
| Total current assets | 1,731.6 | 2,592.3 | |||||||||
Property, plant and equipment, net of accumulated depreciation of $426.5 and $392.2, respectively  | 258.7 | 232.9 | |||||||||
| Other assets | 348.6 | 348.4 | |||||||||
| Goodwill | 7,276.2 | 7,216.0 | |||||||||
| Other intangible assets, net | 2,268.4 | 2,530.5 | |||||||||
| Other assets, discontinued operations | 3.2 | 4,096.0 | |||||||||
| Total assets | $ | 11,886.7 | $ | 17,016.1 | |||||||
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Current portion of long-term debt | $ | 1,189.2 | $ | 376.2 | |||||||
| Trade accounts payable | 427.6 | 425.4 | |||||||||
| Accrued expenses and other current liabilities | 852.7 | 868.3 | |||||||||
| Current liabilities, discontinued operations | — | 568.5 | |||||||||
| Total current liabilities | 2,469.5 | 2,238.4 | |||||||||
| Other long-term liabilities | 788.6 | 847.2 | |||||||||
| Long-term debt | 2,117.1 | 3,331.1 | |||||||||
| Long-term liabilities, discontinued operations | — | 403.8 | |||||||||
| Equity: | |||||||||||
Common stock: $0.01 par value, 2,000 shares authorized; 368.8 and 366.6 issued; 317.6 and 341.2 outstanding, respectively  | 3.7 | 3.7 | |||||||||
| Additional paid-in capital | 4,164.3 | 4,035.0 | |||||||||
| Treasury shares, at cost | (2,962.6) | (1,612.3) | |||||||||
| Retained earnings | 5,264.3 | 8,227.6 | |||||||||
| Accumulated other comprehensive loss | 34.2 | (465.4) | |||||||||
| Total Fortive stockholders’ equity | 6,503.9 | 10,188.6 | |||||||||
| Noncontrolling interests | 7.6 | 7.0 | |||||||||
| Total stockholders’ equity | 6,511.5 | 10,195.6 | |||||||||
| Total liabilities and equity | $ | 11,886.7 | $ | 17,016.1 | |||||||
| Nine Months Ended | |||||||||||
| September 26, 2025 | September 27, 2024 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net earnings | $ | 393.5 | $ | 624.1 | |||||||
| Less: net earnings (loss) from discontinued operations | (52.3) | (334.8) | |||||||||
| Net earnings from continuing operations | 341.2 | 289.3 | |||||||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | |||||||||||
| Amortization | 274.3 | 277.1 | |||||||||
| Depreciation | 52.0 | 45.7 | |||||||||
| Stock-based compensation | 96.9 | 67.1 | |||||||||
| Loss from equity investments | — | 39.4 | |||||||||
| Change in certain assets and liabilities: | |||||||||||
| Change in trade accounts receivable, net | 56.2 | 52.1 | |||||||||
| Change in inventories | (40.2) | (9.2) | |||||||||
| Change in trade accounts payable | (4.1) | 5.0 | |||||||||
| Change in prepaid expenses and other assets | (28.0) | (27.1) | |||||||||
| Change in accrued expenses and other liabilities | (56.8) | (38.6) | |||||||||
| Total operating cash provided by continuing operations | 691.5 | 700.8 | |||||||||
| Total operating cash provided by discontinued operations | 25.8 | 323.8 | |||||||||
| Net cash provided by operating activities | 717.3 | 1,024.6 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Purchases of property, plant and equipment | (74.7) | (63.5) | |||||||||
| Proceeds from sale of property | 0.4 | 0.8 | |||||||||
| Cash paid for acquisitions, net of cash received | — | (3.7) | |||||||||
| All other investing activities | 10.8 | (1.6) | |||||||||
| Total investing cash used in continuing operations | (63.5) | (68.0) | |||||||||
| Total investing cash used in discontinued operations | (15.7) | (1,731.8) | |||||||||
| Net cash used in investing activities | (79.2) | (1,799.8) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Net proceeds from (repayments of) commercial paper borrowings | 105.8 | (571.2) | |||||||||
| Repurchase of common shares | (1,345.1) | (423.0) | |||||||||
| Payment of dividends | (73.4) | (83.9) | |||||||||
| Proceeds from borrowings (maturities greater than 90 days), net of issuance costs | — | 1,733.5 | |||||||||
| Repayment of borrowings (maturities greater than 90 days) | (715.7) | (1,000.0) | |||||||||
| Proceeds from Ralliant Dividend | 1,150.0 | — | |||||||||
| All other financing activities | 15.6 | 47.9 | |||||||||
Total financing cash used in continuing operations  | (862.8) | (296.7) | |||||||||
| Total financing cash used in discontinued operations | (160.3) | — | |||||||||
Net cash used in financing activities  | (1,023.1) | (296.7) | |||||||||
| Effect of exchange rate changes on cash and equivalents | 2.5 | (5.6) | |||||||||
| Net change in cash and equivalents | (382.5) | (1,077.5) | |||||||||
| Beginning balance of cash and equivalents | 813.3 | 1,888.8 | |||||||||
| Ending balance of cash and equivalents | $ | 430.8 | $ | 811.3 | |||||||
| Three Months Ended | |||||||||||||||||||||||||||||||||||
| September 26, 2025 | September 27, 2024 | ||||||||||||||||||||||||||||||||||
| Intelligent Operating Solutions | Advanced Healthcare Solutions | Total Fortive | Intelligent Operating Solutions | Advanced Healthcare Solutions | Total Fortive | ||||||||||||||||||||||||||||||
| Total Revenue Growth (GAAP) | 2.6 | % | 1.9 | % | 2.3 | % | 2.8 | % | 8.3 | % | 4.5 | % | |||||||||||||||||||||||
| Excluding impact of: | |||||||||||||||||||||||||||||||||||
| Divestitures | 0.5 | % | — | % | 0.3 | % | (0.8) | % | — | % | (0.6) | % | |||||||||||||||||||||||
| Currency exchange rates | (0.9) | % | (0.8) | % | (0.7) | % | (0.3) | % | 0.9 | % | 0.1 | % | |||||||||||||||||||||||
| Core Revenue Growth (Non-GAAP) | 2.2 | % | 1.1 | % | 1.9 | % | 1.7 | % | 9.2 | % | 4.0 | % | |||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||
| September 26, 2025 | September 27, 2024 | September 29, 2023 | |||||||||||||||
| Revenue (GAAP) | $ | 1,027.1 | $ | 1,003.7 | $ | 960.6 | |||||||||||
| Net Earnings (GAAP) | $ | 117.0 | $ | 111.5 | $ | 96.1 | |||||||||||
| Interest expense, net | 25.4 | 37.1 | 29.8 | ||||||||||||||
| Income taxes | 18.0 | (2.4) | 15.7 | ||||||||||||||
| Depreciation | 17.6 | 15.8 | 14.8 | ||||||||||||||
| Amortization | 91.5 | 92.0 | 91.8 | ||||||||||||||
| EBITDA (Non-GAAP) | 269.5 | 254.0 | 248.2 | ||||||||||||||
Pretax acquisition and divestiture, and Separation related items  | 38.3 | 0.1 | 1.7 | ||||||||||||||
| Pretax discrete restructuring charges | 2.1 | — | 0.9 | ||||||||||||||
| Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt | (0.5) | — | — | ||||||||||||||
| Pretax losses from equity investments | — | 26.2 | 3.8 | ||||||||||||||
| Adjusted EBITDA (Non-GAAP) | $ | 309.4 | $ | 280.3 | $ | 254.6 | |||||||||||
| Net Earnings Margin from Continuing Operations (GAAP) | 11.4 | % | 11.1 | % | 10.0 | % | |||||||||||
| Adjusted EBITDA Margin from Continuing Operations (Non-GAAP) | 30.1 | % | 27.9 | % | 26.5 | % | |||||||||||
| Three Months Ended September 26, 2025 | Three Months Ended September 27, 2024 | Three Months Ended September 29, 2023  | |||||||||||||||||||||||||||||||||
| $ in millions | Intelligent Operating Solutions | Advanced Healthcare Solutions | Intelligent Operating Solutions | Advanced Healthcare Solutions | Intelligent Operating Solutions | Advanced Healthcare Solutions | |||||||||||||||||||||||||||||
| Revenue (GAAP) | $ | 698.8 | $ | 328.3 | $ | 681.3 | $ | 322.4 | $ | 662.9 | $ | 297.7 | |||||||||||||||||||||||
| Operating Profit (GAAP) | $ | 180.7 | $ | 42.5 | $ | 169.0 | $ | 36.7 | $ | 156.6 | $ | 20.0 | |||||||||||||||||||||||
| Amortization of acquisition-related intangible assets | 46.4 | 45.1 | 46.9 | 45.1 | 46.6 | 45.2 | |||||||||||||||||||||||||||||
Acquisition, divestiture, and Separation related items  | 0.1 | 0.1 | 0.1 | — | 1.7 | — | |||||||||||||||||||||||||||||
| Discrete restructuring charges | 2.0 | 0.1 | — | — | 0.9 | — | |||||||||||||||||||||||||||||
| Adjusted Operating Profit (Non-GAAP) | 229.2 | 87.8 | 216.0 | 81.8 | 205.8 | 65.2 | |||||||||||||||||||||||||||||
| Depreciation | 12.7 | 4.5 | 10.7 | 4.8 | 8.6 | 5.2 | |||||||||||||||||||||||||||||
| Adjusted EBITDA (Non-GAAP) | $ | 241.9 | $ | 92.3 | $ | 226.7 | $ | 86.6 | $ | 214.4 | $ | 70.4 | |||||||||||||||||||||||
| Operating Profit Margin (GAAP) | 25.9 | % | 12.9 | % | 24.8 | % | 11.4 | % | 23.6 | % | 6.7 | % | |||||||||||||||||||||||
| Adjusted Operating Profit Margin (Non-GAAP) | 32.8 | % | 26.7 | % | 31.7 | % | 25.4 | % | 31.0 | % | 21.9 | % | |||||||||||||||||||||||
| Adjusted EBITDA Margin (Non-GAAP) | 34.6 | % | 28.1 | % | 33.3 | % | 26.9 | % | 32.3 | % | 23.6 | % | |||||||||||||||||||||||
| ($ in millions) | Three Months Ended | Trailing Twelve Months | |||||||||||||||||||||||||||
| September 26, 2025 | June 27, 2025 | March 28, 2025 | December 31, 2024 | ||||||||||||||||||||||||||
| Operating Cash Flows (GAAP) | $ | 294.7 | $ | 205.0 | $ | 191.8 | $ | 327.7 | $ | 1,019.2 | |||||||||||||||||||
| Less: Purchases of property, plant & equipment (capital expenditures) (GAAP) | (28.6) | (25.0) | (21.1) | (22.6) | (97.3) | ||||||||||||||||||||||||
| Free Cash Flow (Non-GAAP) | $ | 266.1 | $ | 180.0 | $ | 170.7 | $ | 305.1 | $ | 921.9 | |||||||||||||||||||
| ($ in millions) | Three Months Ended | Trailing Twelve Months | |||||||||||||||||||||||||||
| September 27, 2024 | June 28, 2024 | March 29, 2024 | December 31, 2023 | ||||||||||||||||||||||||||
| Operating Cash Flows (GAAP) | $ | 304.7 | $ | 217.5 | $ | 178.6 | $ | 259.8 | $ | 960.6 | |||||||||||||||||||
| Less: Purchases of property, plant & equipment (capital expenditures) (GAAP) | (21.6) | (19.6) | (22.3) | (23.4) | (86.9) | ||||||||||||||||||||||||
| Free Cash Flow (Non-GAAP) | $ | 283.1 | $ | 197.9 | $ | 156.3 | $ | 236.4 | $ | 873.7 | |||||||||||||||||||